Full-Time

Long-Term Care Sales Account Manager

Deadline 7/8/27
Shionogi

Shionogi

501-1,000 employees

Specialty pharma marketing pain and anti-infectives

Compensation Overview

$125k - $175k/yr

+ Vehicle allowance + Bonus + Long-term incentive + Additional compensation

Atlanta, GA, USA

In Person

Approximately 80% field travel is required; some overnight or weekend travel may be required.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Sales
Word/Pages/Docs
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Shionogi

See people who can refer or advise you

Requirements
  • A Bachelor's Degree (BA or BS) is preferred.
  • A minimum of five years of sales experience in the pharmaceutical or healthcare industry, including experience selling into long-term care settings, or three years of pharmaceutical sales experience with recent experience in a Long-Term Care Account Manager or similar role, or three to five years of clinically focused experience in a long-term care setting is required.
  • Experience calling on skilled nursing facilities, assisted living facilities, long-term care pharmacies, or consultant pharmacist networks is required.
  • Experience in building rapport and relationships within the long-term care setting to expand product awareness and utilization is required.
  • The candidate must be able to understand and navigate long-term care systems to gain access to key decision makers.
  • Proficiency in Veeva Customer Relationship Management, Microsoft Teams, Outlook, and calendar-based call-planning tools is required.
  • Business-to-business experience and the ability to demonstrate strong influencing skills are required.
  • A documented record of demand generation, performance, and achievement in long-term care is required.
  • Successful long-term care launch experience is required.
  • Excellent oral, presentation, and written communication skills are required.
  • Strong clinical acumen and the ability to communicate clinical data and a high-level scientific product are required.
  • Strong organizational, interpersonal, and listening skills are required.
  • The candidate must be able to work independently and collaborate internally as a team member to deliver results.
  • The candidate must demonstrate problem-solving skills, initiative, and motivation.
  • Digital competence and the ability to deliver presentations digitally using an iPad are required.
  • Proficiency in the Microsoft Office Suite, including Word, PowerPoint, Excel, and Outlook, is required.
  • The candidate must complete the full onboarding curriculum, including clinical modules, Customer Relationship Management documentation, and fair-balance call standards.
  • The candidate must pass live-call certification and mock-objection assessments during ride-along training.
  • The candidate must attend refresher meetings on disease-state updates, HUB workflows, and patient-retention strategy.
  • Significant field travel of approximately 80% is required.
  • A valid driver's license, a clean driving record, and the ability to pass a complete background check are required.
  • The candidate must hold valid licenses and credentials required to conduct business in the assigned territory.
  • The candidate must be able to drive or fly to target accounts, customers, meetings, and conventions.
  • The candidate must be able to articulate clearly and conduct verbal presentations with large and small audiences.
  • The candidate must be able to travel by automobile and airplane.
  • The candidate must be able to view video-display-terminal images less than 18 inches from the face for extended periods of up to four hours at a time.
  • The candidate must be able to operate a computer keyboard and telephone.
  • The candidate must be able to sit for extended periods of up to four hours at a time.
  • The candidate must be able to lift, tug, or pull up to 15 pounds.
Responsibilities
  • Establish clinical understanding, access, and sales demand within the long-term care sector for target accounts.
  • Call on long-term care facilities and affiliated business entities through one-on-one meetings, presentations, professional education programs, and other appropriate means to educate healthcare professionals, medical directors, administrators, directors of nursing, consultant pharmacists, and pharmacy directors about clinical profile, access processes, and appropriate utilization.
  • Execute and track a high level of call and field productivity and meet or exceed target account and customer calls per day.
  • Analyze territory information and insights to develop and execute target mapping and account plans, optimize routing, and maximize field resources.
  • Establish professional relationships and maintain an effective communication network with customers at multiple levels.
  • Develop and implement sales strategies to achieve sales targets and expand access and utilization.
  • Execute brand sales strategies to ensure a consistent company marketing message.
  • Manage and grow existing accounts within the long-term care sector.
  • Partner with reimbursement and market-access teams to address patient-access issues proactively.
  • Conduct company business in accordance with applicable regulations, company policies, and procedures.
  • Maintain comprehensive call documentation, access barriers, and response metrics in Veeva Customer Relationship Management.
  • Report field activities and territory expenses accurately and submit written reports by required deadlines.
  • Maintain accurate records of sales activities, customer interactions, and market feedback.
  • Identify and communicate field issues, opportunities, and competitive activities through appropriate organizational channels and escalate emerging utilization gaps, drop-offs, and prescriber feedback.
  • Collaborate with Regional Account Management, Market Access, Medical Affairs, and Marketing on customer needs, opportunities, touchpoints, and changes.
  • Represent the company at long-term-care-focused medical and pharmacy association events.
  • Create opportunities for product education while enhancing the company's image and commitment to medicine by working with local and regional thought leaders and professional societies.
  • Manage and maintain company equipment and promotional materials according to company guidelines.
  • Pursue continuous learning and professional development in sales, communication, managed care, and product knowledge.
  • Attend company-sponsored meetings, including POAs, national meetings, and national or regional conventions, as directed by management.
  • Maintain a deep understanding of company products, industry trends, and competitor activities.
  • Provide customer service and support to ensure customer satisfaction and loyalty.
Desired Qualifications
  • Experience selling in a complex reimbursement and access environment is highly preferred.
  • An in-depth understanding of the pharmaceutical industry, product launch strategies, and long-term care markets and practices, including pharmaceutical product review, is highly preferred.

Shionogi expanded its U.S. portfolio by acquiring Victory Pharma’s marketed products, focusing on pain management and anti-infectives. Victory Pharma developed and marketed prescriptions such as Naprelan (a controlled-release naproxen) and anti-infectives like MOXATAG and KEFLEX for pain, rheumatology, and infectious diseases. Shionogi uses its existing U.S. sales force to market these FDA-approved products to doctors, quickly establishing a market presence. The strategy aims to grow in the United States by integrating Victory Pharma’s products into Shionogi’s sales and marketing reach, though Victory Pharma later faced a federal settlement related to promotional practices.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Florham Park, New Jersey

Founded

2001

Get referred to Shionogi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 ALS consortium partnership deepens real-world evidence around RADICAVA and ALS.
  • June 2026 Dioseve investment expands optionality beyond infectious disease into reproductive medicine.
  • April 2026 BARDA funding de-risks U.S. cefiderocol supply, manufacturing, and pediatric expansion.

What critics are saying

  • Xofluza faces generic pressure after July 2025 Norwich settlement and 2026 MPP licensing.
  • XOCOVA’s U.S. launch depends on sustained exposure-driven COVID demand after summer 2026.
  • RADICAVA’s $2.5 billion acquisition needs rapid sales growth; weak uptake strains capital.

What makes Shionogi unique

  • Shionogi controls XOCOVA, the only U.S. oral COVID-19 post-exposure prophylaxis, June 2026.
  • Its April 2026 RADICAVA acquisition added global ALS rights and commercial infrastructure.
  • BARDA’s April 2026 $482 million cefiderocol contract anchors U.S. manufacturing and procurement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

401(k) Retirement Plan

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
ADRBNY
Aug 5th, 2026
StreetAccount summary - asian market recap: Nikkei +3.66%, Hang Seng +0.24%, Shanghai Composite +1.47% as of 04:10 ET.

StreetAccount summary - asian market recap: Nikkei +3.66%, Hang Seng +0.24%, Shanghai Composite +1.47% as of 04:10 ET. Aug 05 ,2026 * Synopsis: * Asia equities rallied almost everywhere for a second consecutive day Wednesday. Technology-leaning benchmarks in South Korea, Taiwan and Japan saw the sharpest gains, while Shenzhen outperformed in mainland China. Hong Kong and Shanghai saw more modest gains while Australia's ASX reached a fresh record high. India has pared early gains while Southeast Asia is mixed. US futures higher, Europe opened with modest gains. US dollar unchanged, NZD slipped after strong jobs data, yuan and yen flat. Treasuries mixed, JGB yields lower, IGBs unchanged following RBI decision. Precious metals rallying with gold at a two-month high. Crude futures seeing more declines as Brent falls below $79/bl. Base metals higher again. Cryptocurrencies mixed. * Asia equities rallied further Wednesday following the overnight surge on Wall Street that took the S&P 500 to a fresh record high, and as futures indicate another strong open this morning in the US. SpaceX's after-hours share price decline unlikely to dissuade the bulls who received support overnight from Treasury Secretary Bessent who said a deal with Iran was imminent and an Axios report that said the US, Iran and Oman would announce an agreement to reopen the Strait of Hormuz later today. Asia equities received a further boost as the dollar remained at six-week lows, boosting local currencies and providing an additional tailwind. * In other developments, China's RatingDog Services PMI declined by more than expected and service growth in Japan also slowed; Singapore full PMI expanded further as new orders and output expanded further. Japan real wages rose for a sixth consecutive month. India's central bank kept its repo rate steady, raised its FY GDP growth forecast and lowered inflation projections but warned over risks to both forecasts from weather and geopolitical developments. * Zhongji Innolight (3308.HK) shares under pressure on a report saying the US was drafting a ban on the import of China-made optical receivers. Shein (+SHEIN) is targeting a $30-40B valuation in its Hong Kong IPO later this month, sources told Reuters. CXMT (688825.CH) is set to produce smartphone memory chips on par with industry's best, according to sources cited by Bloomberg. Shionogi's (4507.JP) CEO said the company is actively pursuing at least three acquisitions, and is considering an expansion in the US. Wistron (3231.TT) says AI server demand remains strong as quarterly profits more than double. Coupang (CPNG) posted a net quarterly loss following fines connected to its massive data breach last November. Samsung Electronics (005930.KS) and SK Hynix (000660.KS) are testing China-made chip tools as hedge against US risk, according to a Reuters report. * Digest: * Notable Gainers: * +24.5% 4062.JP (IBIDEN): reports Q1 results; revenue and operating profit beat FactSet estimates; raises FY guidance * +8.1% 669.HK (Techtronic Industries): reports H1 results * +5.0% 3034.TT (Novatek Microelectronics): reports Q2 EPS NT$10.40 vs FactSet NT$7.93 * +4.7% 9434.JP (SoftBank Corp): reports Q1 results; revenue and operating profit beat StreetAccount estimates * +4.0% 5401.JP (NIPPON STEEL): reports Q1 results; revenue and business profit beat FactSet estimates * +3.8% 196170.KS (Alteogen): signs exclusive license agreement for ALT-B4 * +1.8% 017670.KS (SK Telecom): reports Q2 results; operating profit beats StreetAccount estimates * Notable Decliners: * -6.8% 293490.KS (Kakao Games): reports Q2 results; revenue misses FactSet estimates * -6.3% 6367.JP (DAIKIN INDUSTRIES): reports Q1 results; net income misses FactSet estimates * -5.1% 4980.JP (Dexerials): reports Q1 results; revenue below FactSet estimates * -3.4% 3064.JP (MonotaRO): reports H1 results * Data: * Economic: * China July * July RatingDog Services PMI 50.4 vs consensus 53.7 and 54.1 in prior month * Composite PMI 50.8 vs 53.6 in prior month * India July * Final services PMI 53.3 vs flash 53.1 and 57.4 in prior month * Composite PMI 54.3 vs flash 54.3 and 57.1 in prior month * Japan * June average nominal wages +3.4% y/y vs consensus +3.4% and revised +3.3% in prior month * Real wages +1.6% y/y vs consensus +1.6% and revised +1.6% in prior month * July final services PMI 51.2 vs flash 51.9 and 52.2 in prior month * Composite PMI 52.7 vs flash 53.1 and 52.8 in prior month * New Zealand Q2 * Employment +0.5% q/q vs consensus +0.1% and revised +0.1% in Q1 * Unemployment rate 5.6% vs consensus 5.4% and 5.3% in Q1 * Singapore June * Retail sales y/y +4% versus +2.9% in prior month * Markets: * Nikkei: 2,342.91 or +3.66% to 66300.44 * Hang Seng: 62.90 or +0.24% to 25915.82 * Shanghai Composite: 56.15 or +1.47% to 3878.43 * Shenzhen Composite: 51.45 or +2.07% to 2537.55 * ASX200: 82.00 or +0.90% to 9227.80 * KOSPI: 239.31 or +3.76% to 6598.26 * SENSEX: (19.38) or (0.02%) to 78409.57 * Currencies: * $-¥: +0.01 or +0.01% to 157.7490 * $-KRW: (4.12) or (0.29%) to 1425.6000 * A$-$: +0.00 or +0.01% to 0.7046 * $-INR: (0.01) or (0.01%) to 95.1646 * $-CNY: (0.00) or (0.07%) to 6.7485

Ochre Digi Media Pvt. Ltd.
Jul 29th, 2026
Shionogi launches XOCOVA in the U.S. for prevention of COVID-19 following exposure.

Shionogi launches XOCOVA in the U.S. for prevention of COVID-19 following exposure. Wednesday, July 29, 2026 Shionogi has announced the U.S. availability of XOCOVA(R)(ensitrelvir), the first and only oral antiviral approved to help prevent COVID-19 after exposure. The treatment is indicated for adults and adolescents aged 12 years and older who have been in contact with someone infected with COVID-19 and is now available through the company's U.S. subsidiary, Shionogi Inc. XOCOVA works by blocking viral replication during the period between exposure to the virus and the onset of symptoms. The treatment is taken once daily for five days, beginning with a loading dose of 375 mg on the first day, followed by 125 mg once daily on days two to five. It should be started as soon as possible and within 72 hours of exposure to an infected individual. The launch comes as health authorities continue to monitor seasonal increases in COVID-19 cases in the United States. The company highlighted that post-exposure prophylaxis is an established approach used for other infectious diseases and may help reduce the burden of COVID-19 by preventing infection after exposure. Shionogi is supporting the commercial rollout of XOCOVA through healthcare professional and public education programmes, alongside partnerships with national and regional pharmacy networks to improve product availability across the United States. The company is also offering a co-pay assistance programme for eligible commercially insured patients to help reduce out-of-pocket costs. For the U.S. market, all stages of XOCOVA manufacturing, including active pharmaceutical ingredient production, drug formulation, packaging, quality control, release testing, supply chain management and distribution, are carried out within the United States.

ALS Canada
Jul 21st, 2026
ALS Canada announces The Shionogi Canada Fellowship for 2025.

ALS Canada announces The Shionogi Canada Fellowship for 2025. July 21, 2026 The ALS Society of Canada (ALS Canada) is pleased to continue its collaboration with Shionogi Canada (previously Tanabe Pharma Canada) to advance excellence in ALS clinical care through The Shionogi Canada Fellowship (previously the Tanabe Pharma Canada Fellowship). This annual fellowship supports emerging clinicians and researchers who are committed to improving care for people living with ALS while strengthening their research expertise. This year, Dr. Pedro Saldanha de Castro will receive $100,000 over one year to support his work at Sunnybrook Research Institute under the supervision of Dr. Agessandro Abrahao. "Shionogi Canada's continued commitment enables ALS Canada to invest in the development of early career researchers across the ALS ecosystem," said Dr. David Taylor, Chief Scientific Officer at ALS Canada. "By applying Dr. Saldanha de Castro's novel integration of two well-studied approaches, this project may help clarify the biological drivers of disease variability in ALS, inform more precise clinical trial design, and support the development of personalized therapeutic strategies." The 2025 fellowship project titled, Innovative multimodal 7T MR imaging to assess cortical excitability and disease subtypes in ALS, aims to use advanced neuroimaging and other tests to compare two groups of people living with ALS: those whose neurons are overactive and those whose neurons are less active. By doing this, the team hopes to identify differences in brain chemistry, structure, and clinical severity between ALS subtypes. They will also validate a novel Magnetic Resonance Spectroscopy method for measuring neurochemicals across large brain regions, which could help doctors better understand the disease and develop treatments tailored to each person's needs. ALS Canada is grateful to Shionogi Canada for its continued partnership and shared commitment to fostering the next generation of ALS clinical leaders. Support the cause You can make a difference. Donations provide crucial services and information to people living with ALS and allow ALS to invest in research and advocacy dedicated to improving quality of life.

Shionogi & Co., Ltd.
Jun 20th, 2026
Shionogi Announces Investment in Dioseve, Inc. through Its CVC Activities

OSAKA, Japan, June 12, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; hereinafter, "Shionogi") today announced that, as part of its corporate venture capital (CVC) initiatives, it has invested in Dioseve, Inc. (Head Office: Tokyo, Japan; hereinafter, "Dioseve")

PharmaTutor
Jun 2nd, 2026
FDA approves Shionogi's Xocova as first oral drug to prevent COVID-19 after exposure.

FDA approves Shionogi's Xocova as first oral drug to prevent COVID-19 after exposure. 2 June 2026 / 0 Comments The U.S. Food and Drug Administration (FDA) has approved Xocova (ensitrelvir), developed by Japanese pharmaceutical company Shionogi & Co., for the prevention of COVID-19 following exposure to an infected individual. The approval makes Xocova the first and only oral antiviral therapy authorized in the United States for post-exposure prophylaxis of COVID-19. The newly approved indication covers adults and adolescents aged 12 years and older who have been exposed to someone with COVID-19. Until now, no oral medication had demonstrated sufficient evidence to gain FDA approval for preventing symptomatic COVID-19 after exposure, leaving a significant gap in prevention strategies, particularly for individuals at higher risk of severe disease. FDA's decision was based on results from the Phase 3 SCORPIO-PEP study, which evaluated ensitrelvir as a post-exposure preventive treatment. According to Shionogi, the trial met its primary endpoint by significantly reducing the development of symptomatic COVID-19 among people who had recently been exposed to the virus. The study is considered the first successful Phase 3 trial of an oral antiviral for COVID-19 post-exposure prevention. The pivotal SCORPIO-PEP trial enrolled more than 2,000 participants who had been exposed to COVID-19 through infected household contacts. Symptomatic COVID-19 developed in 2.9% of participants receiving ensitrelvir compared with 9.0% in the placebo group. Additionally, 14% of patients receiving the antiviral tested positive for SARS-CoV-2 versus 21.5% in the placebo arm, highlighting the drug's potential to reduce both infection and disease development after exposure. Ensitrelvir works by blocking the SARS-CoV-2 main protease, an enzyme essential for viral replication. The drug was previously approved in Japan and Singapore for COVID-19 treatment and prevention-related indications. With the latest FDA approval, Shionogi expands its presence in the global COVID-19 therapeutics market and introduces a new option for reducing infection risk after exposure. Company officials described the approval as an important milestone in antiviral drug development. They noted that Xocova demonstrated preventive benefits regardless of vaccination status or previous COVID-19 infection history among study participants. The approval comes as healthcare systems continue to seek effective tools to protect vulnerable populations from COVID-19 outbreaks. Experts believe an oral post-exposure treatment could be particularly useful in households, healthcare settings, and other environments where close contact with infected individuals increases transmission risk.